Wayne State University
Wayne State University Dissertations
January 2018

Zwitterionic Polymer For Drug Delivery Applications
Yang Lu
Wayne State University, fj4608@wayne.edu

Follow this and additional works at: https://digitalcommons.wayne.edu/oa_dissertations
Part of the Chemical Engineering Commons

Recommended Citation
Lu, Yang, "Zwitterionic Polymer For Drug Delivery Applications" (2018). Wayne State University
Dissertations. 2046.
https://digitalcommons.wayne.edu/oa_dissertations/2046

This Open Access Dissertation is brought to you for free and open access by DigitalCommons@WayneState. It has
been accepted for inclusion in Wayne State University Dissertations by an authorized administrator of
DigitalCommons@WayneState.

ZWITTERIONIC POLYMER FOR DRUG DELIVERY APPLICATIONS
by
YANG LU
DISSERTATION
Submitted to the Graduate School
of Wayne State University,
Detroit, Michigan
in partial fulfillment of the requirements
for the degree of
DOCTOR OF PHILOSOPHY
2018
MAJOR: CHEMICAL ENGINEERING
Approved By:

Advisor

Date

© COPYRIGHT BY
YANG LU
2018
All Rights Reserved

ACKNOWLEDGMENTS
At first, I would like to express my sincere gratitude to my advisor Prof Zhiqiang Cao for
the continuous support of my Ph.D. study and research, for his encouragement, motivation, and
many tips both on research and personal careers. His guidance helped me to improve myself to
know how to dedicate to research and increase working efficiency. During the past 5 years, he
always teaches me how to be a researcher and helped me to overcome obstacles. It’s hard for me
to reach the requirement of Ph.D. graduate without his help and guidance.
In addition, I would like to thank all other thesis committee members: Prof. Haipeng Liu,
Prof. Matthew Allen, and Prof. Steven Salley, for their attending, supporting and insightful
advice.
I would also like to thank my fellow labmates: Dr. Wei Wang, Hui Zhu, Dr. Ershuai Zhang,
Dr. Jianhai Yang, Dr. Hong Du, Xiangfei Han and Hanyu Jia, for the insightful discussion, for
the time working together and their kind help on my research study.
Last, I would like to thank my parents, for giving birth to me at the first place and
supporting me throughout my life.

ii

TABLE OF CONTENTS

Acknowledgments ........................................................................................................................................ ii
LIST OF TABLES ........................................................................................................................................ v
LIST OF FIGURES ..................................................................................................................................... vi
Chapter 1. Introduction ................................................................................................................................. 1
Chapter 2. Discovery of Ultra-low CMC Zwitterionic Micelles .................................................................. 6
2.1 Introduction ......................................................................................................................................... 6
2.2 Materials and Methods ........................................................................................................................ 8
2.2.1 Material ........................................................................................................................................ 8
2.2.2 Preparation of gold nanoparticles (NPs) encapsulated by DSPE-PCB 5K .................................. 8
2.3 Results and Discussion........................................................................................................................ 9
Chapter 3 Therapeutic Performance of drug/DSPE-PCB 5K formulation ................................................. 31
3.1 Introduction ....................................................................................................................................... 31
3.2 Materials and Methods ...................................................................................................................... 32
3.2.1 Materials .................................................................................................................................... 32
3.2.2 Preparation of docetaxel/DSPE-PCB 5K formulation ............................................................... 32
3.2.3 Animal Experiments .................................................................................................................. 33
3.3 Results and Discussion...................................................................................................................... 35
Chapter 4. Simple protein modification using zwitterionic polymer .......................................................... 46
4.1 Introduction ....................................................................................................................................... 46
4.2 Materials and Methods ...................................................................................................................... 47
4.2.1 Materials .................................................................................................................................... 47
4.2.2 Synthesis of PCB-(N-hydroxysuccinimide) (NHS) ................................................................... 48
4.2.3 Synthesis of PCB-insulin and PEG-insulin................................................................................ 48
4.2.4 Purification of PCB-insulin and PEG-insulin ............................................................................ 49
iii

4.2.5 Other Characterization ............................................................................................................... 49
4.2.6 Animal Experiments .................................................................................................................. 50
4.3 Results and Discussion...................................................................................................................... 51
Chapter 5. Conclusion................................................................................................................................. 63
Abstract ....................................................................................................................................................... 69
Autobiographical statement ........................................................................................................................ 70

iv

LIST OF TABLES
Table 4-1 The relative area under the curve (AUC) and elimination half-life (t1/2) of native
insulin and its conjugates in blood serum. Data are illustrated by average ± standard deviation,
n=6…...…………………………………………………………………………………………. 59
Table 4-2 The secondary structure proportion of insulin samples measured from Circular
Dichroism (CD) Spectroscopy……………………………………………………….…………. 61

v

LIST OF FIGURES
Figure 2-1. Ultra-low-CMC micelles and their unusual ability to stabilize cargoes in extremely
diluted conditions with micelle concentrations far below CMCs of common micelles.
Conventional micelles dissociate at a concentration below CMC, and thus cannot stabilize a
hydrophobic cargo. Structure for ultra-low-CMC micelles is shown. For conventional micelles,
their polar groups were either non-ionic (e.g., Polysorbate 80, having hydrophobic nature), or
only contained one ionic group (e.g., sodium dodecyl sulfate). Sharp-contrast micelles with
multiple polar zwitterionic (polyzwitterionic) groups were recently reported. …………..…17
Figure 2-2. TEM and DLS data of DSPE-PCB 5K micelle. a, Representative TEM image for
DSPE-PCB 5K micelle (5 mM) in water taken by JEOL 2010 Transmission electron microscopy.
Stained with 2% uranyl acetate. The scale bar in the figure is 50 nm. b, DLS data for DSPE-PCB
5K in PBS (0.5 mM), showing an average diameter of 20 ± 3.5 nm (mean ± SD, N = 3) with a
polydispersity index of 0.13………………...………………………………………...………….18
Figure 2-3. The hydrophobic core domains of DSPE-PCB 5K micelle were detected using
pyrene as reflected by the decrease in the intensity ratio of the first to the third highest energy
bands (I1/I3) in the emission spectra of pyrene from 1.7 in water (a) to 1.16 in 0.17 mg/ml micelle
in water (b). The excitation wavelength was 334 nm ……………………………………...18
Figure 2-4. The CMC of DSPE-PCB 5K was determined to be 1.3 x 10-3 mM using the pyrene
probe method (mean ± SD, N=3) …………………………………...………………….………19
Figure 2-5. “Diluting-concentrating” method to probe CMCs for micelles. Aggregation of the
gold probe at different micelle concentrations was reflected by a, hydrodynamic size of the
colloid and b, gold maximum absorbance wavelength (mean ± SD, N=3). Dashed arrow in both
figures indicate the CMC values. CMC data for DSPE-PEG are from reference. CMC data for
other commercial available micelles are provided by the manufacturer……………...…….… 20
Figure 2-6. “Diluting-concentrating” method to determine micelle CMCs using gold NP as a
probe. Measuring curves for all samples tested are shown (a-j), including non-ionic, cationic,
anionic, and zwitterionic surfactants. Aggregation of the gold probe at different micelle
concentrations was reflected by the hydrodynamic size of the colloid and gold maximum
absorbance wavelength (mean ± SD, N=3). Known CMC values for micelles were listed and
indicated by dashed arrows. The current “diluting-concentrating” method is able to detect a CMC
as low as 2.7 x 10-6 mM. ……………………………………………………………………….25
Figure 2-7. CaCO3 probes were encapsulated in DSPE-PCB 5K micelle, by dissolving micelles
and CaCl2 in 10 ml deionized water followed by dropwise addition of 1 ml Na2CO3 aqueous
solution under vigorous stirring at room temperature for 15 min (micelle:CaCl2:Na2CO3 (molar
ratio) = 1:1:1). (a) The size of DSPE-PCB 5K/CaCO3 nanoparticles before dilution. Micelle
concentration was 3 mg/mL (0.5 mM), and CaCO3 concentration was 0.05 mg/mL (0.5 mM). (b)
The size of DSPE-PCB 5K/CaCO 3 nanoparticles after 1000-fold dilution to micelle
vi

concentration of 5 x 10-7 M, and CaCO3 concentration of 0.05mg/L, and then concentrated back
to the original concentration at (a). The solubility of CaCO3 in water is 0.013 g/L or 13 mg/L.
The concentration of CaCO3 encapsulated in micelle before dilution (0.05 mg/mL) was above its
solubility (0.013 mg/mL), and the concentration of CaCO3 encapsulated in micelle after dilution
(0.05 mg/L) was below its solubility (13mg/L). CaCO 3 was found to be released at diluted
concentration and aggregated into large particles after condensation as shown at (b)……….….26
Figure 2-8. TEM figures of DSPE-PCB 5K micelle at an extremely low concentration (2.7×10-6
mM). Stained with 2% uranyl acetate. The scale bar in the figure is 20 nm. …………….....…. 26
Figure 2-9. Effect of supplying zwitterionic moieties decreases CMCs of conventional micelles,
and the impact of zwitterionic PCB MW on the CMC of DSPE-PCB. a,b, Gold NPs were loaded
in SDS(a) and Polysorbate 80 (b), respectively, and upon water dilution, their aggregation
behavior (due to micelle dissociation) was measured by the increase in maximum absorbance
peak of gold (mean ± SD, N=3). When 500 mg/mL CB was used as dilution solvent, no
significant gold NP aggregation was observed in the dilution range, indicating a significantly
stabilized micelle (despite a concentration below its inherent CMC). In contrast, when 500
mg/ml OEG was used as dilution solvent, there was gold NPs aggregation at high micelle
concentrations, showing an increase of micelle CMC. CB and OEG alone (without the aid of
micelles) cannot stabilize gold NPs, leading to severe aggregation. It should be noted that DLS
data are not reliable in this experiment since the large concentration of small-sized CB or OEG
moieties interferes with the hydrodynamic size readings for aggregated gold NPs. c, d, “Dilutingconcentrating” method to probe CMCs for DSPE-PCB 2K, 5K, 10K micelles. Aggregation of the
gold probe at different micelle concentrations was reflected by the gold maximum absorbance
wavelength (c) (mean ± SD, N=3) and the hydrodynamic size of the colloid (d) (mean ± SD,
N=3). CMC values were determined for DSPE-PCB 2K and 10K are indicated by dashed
arrows…………………………………….....................................................................................27
Figure 2-10. Gold NPs were loaded in SDS (a) and Polysorbate 80 (b) respectively, and upon
water dilution, their aggregation behavior (due to micelle disassociation) was measured by the
increase in maximum absorbance peak of gold (mean ± SD, N=3). When 100 mg/mL PCB
polymer (MW= 5K) was used as dilution solvent, no gold nanoparticle aggregation was observed
in the dilution range, indicating micelle were stabilized even at a concentration below its inherent
CMC. In contrast, when 100 mg/mL PEG polymer (MW= 5K) was used as dilution solvent,
there was gold NP aggregation at concentrations above it inherent CMC of micelles. PCB and
PEG alone (without the aid of micelles) cannot stabilize gold NPs, leading to severe aggregation.
It should be noted that DLS data are not reliable in this experiment since the presence of a large
concentration of small size PCB or PEG interferes with the hydrodynamic size reading for the
aggregated gold NPs. Different concentration of PCB solutions was used as dilution solvent, and
within the concentration series, 40 mg/mL PCB was the minimum required to stabilize (c) SDS
and (d) Polysorbate 80 upon dilution (mean ± SD, N=3). Different concentration of CB solutions
were used as dilution solvents, and within the concentration series 200 mg/mL CB was the
minimum required to stabilize (e) SDS and (f) Polysorbate 80 upon dilution (mean ± SD,
N=3). ……………………………………………….………………………...…………….….29

vii

Figure 2-11. Stability of ultra-low-CMC micelle and conventional micelles with gold NP probes
encapsulated at 5.5 × 10-2 mM micelle concentration in 100% fetal bovine serum (FBS) over 72
h at room temperature. Potential micelle disassociation resulted in gold NPs aggregation, which
was measured by gold maximum absorbance peak (mean ± SD, N=3). Known CMC values for
each micelle are indicated inside the graph. …………………………......……………..……… 29
Figure 3-1. Stability of different docetaxel formulation diluted in FBS (mean ±SD, N=3). ..... 38
Figure 3-2. The release profile of different docetaxel formulations in the dialysis tube against
PBS. (mean ± SD, N=3) ……………………………….………………………………...………38
Figure 3-3. Stability of different docetaxel formulations as reflected by the hydrodynamic size of
the formulation before and after lyophilization (mean ± SD, N = 3). The circles in each bar
represent an original data point…………………………………………………………………..39
Figure 3-4. Dose escalation in healthy mice. Solutions of different formulations a, Taxotere; b,
docetaxel/DSPE-PCB; c, docetaxel/DSPE-PEG; d, docetaxel/Polysorbate 80 were administered
through intravenous tail vein injection. (mean ± SD, N=3). …………………………………….41
Figure 3-5. (a)Anti-tumor performance of docetaxel/DSPE-PCB 5K formulation (mean ± SD, N
= 7) compared with other formulations (mean ± SD, N = 7). On day 10 after treatment (*), a
Mann-Whitney Test indicated that docetaxel/DSPE-PCB 5K delayed the tumor growth greater
than all other four controls at p = 0.005 (b), Survival rate curves of mice treated with the
different formulations. (c), Probability of cure. In mice bearing invisible tumors < 1mm 3 in size
or a flattened and darkened scar tissue developed, it was considered that the tumor had been
completely eradiated. Line represent docetaxel/DSPE-PEG 5K, docetaxel/polysorbate 80,
taxotere and PBS are overlapped………………………………………………………………...42
Figure 3-6. The concentration of docetaxel in blood plasma of different formulations (mean ±
SD, N = 4). …………………………………………………………………………………...... 43
Figure 3-7. Bio-distribution of different docetaxel formulations at 24 hours post i.v. injection
(mean ± SD, N= 4). One-Way ANOVA analysis with Bonferroni multi-comparison: significant
difference between docetaxel/DSPE-PCB 5K and docetaxel/DSPE-PEG 5K, docetaxel/DSPEPCB 5K and docetaxel/Polysorbate 80, docetaxel/DSPE-PCB 5K and Taxotere, at p < 0.001
(***), p < 0.0001 (****), and p < 0.0001 (****), respectively. ...…...………………………….44
Figure 3-8. Bio-distribution of different docetaxel formulations. a, bio-distribution of docetaxel
from different formulations at 2 hours post i.v. injection (mean ± SD, N= 4). One-Way ANOVA
analysis with Bonferroni multi-comparison: significant difference between docetaxel/DSPE-PCB
5K and docetaxel/Polysorbate 80, docetaxel/DSPE-PCB 5K and Taxotere, at p < 0.01 and p <
0.05, respectively. No significant difference between docetaxel/DSPE -PCB 5K and
docetaxel/DSPE-PEG 5K. b, bio-distribution of docetaxel from different formulations at 8 hours
post i.v. injection (mean ± SD, N= 4). One-Way ANOVA analysis with Bonferroni multiviii

comparison: significant difference between docetaxel/DSPE-PCB 5K and docetaxel/DSPE-PEG
5K, docetaxel/DSPE-PCB 5K and docetaxel/Polysorbate 80, docetaxel/DSPE-PCB 5K and
Taxotere, at p < 0.01, p < 0.0001, and p < 0.001, respectively………………………………....44
Figure 4-1. (a) The schematic illustration of PCB conjugation with native recombinant human
insulin. There are three amino acids with free amino groups (GlyA1, PheB1, and Lys B29) that
are available for PCB conjugation. The disulfide bonds in insulin were labeled with yellow sticks.
(b) MALDI-TOF Mass spectra of native insulin, PEG-insulin, and PCB-insulin. …….…..……58
Fig. 4-2 (a) Hydrodynamic sizes for free insulin, PEG-insulin, and PCB-insulin, respectively, as
measured by DLS. Samples were dissolved in 0.2 M pH8.4 HEPES buffer. (b) The serum insulin
concentration as a function of time after the tail vein injection of free insulin, PEG-insulin, and
PCB-insulin, respectively. The data are presented as the percentage of the initial values of serum
insulin concentration over time ± standard deviation (n=6). ………………..…………….….... 59
Fig. 4-3 (A) Circular dichroism (CD) spectra of native insulin, PEG-insulin, and PCB-insulin
(0.2 mg/mL insulin or conjugates at 0.2 M pH8.2 PBS buffer), respectively. (B) The bioactivity
of native insulin, rough PEG-insulin, purified PEG-insulin, rough PCB-insulin, and purified
PCB-insulin, respectively, as measured by phosphorylation of the insulin receptor in vitro. The
relative activity was presented as the percentage relative to native insulin ± standard deviation
(n=6). *p < 0.05, **p < 0.01, n.s.=not significant. The relative blood glucose concentration as a
function of time after the tail vein injection of free insulin, PEG-insulin, and PCB-insulin (C)
before and (D) after purifying insulin conjugate products. The data are presented as the
percentage of the initial values of blood glucose concentration ± standard deviation
(n=6).……………...………………………………………………………………….….…….... 60
Figure 4-4: MALDI-TOF Mass spectra of native insulin, purified PEG-insulin and purified
PCB-insulin where most of the three amines of insulin were conjugated with PEG or
PCB. ………………………………………………………………………………………….… 61
Figure 4-5: (A) The bioactivity of native insulin, rough PEG-insulin, purified PEG-insulin,
rough PCB-insulin and purified PCB-insulin, respectively, as measured by phosphorylation of
the insulin receptor in vitro. For the polymer-insulin tested, most of the three amines of insulin
were conjugated with PEG or PCB. The relative activity was presented as the percentage of
native insulin (n=6). *** p < 0.001. (B) The relative blood glucose concentration as a function of
time after the tail vein injection of free insulin, rough PEG-insulin, and rough PCB-insulin
(before purifying insulin conjugate products). The data are presented as the percentage of the
initial values of blood glucose concentration ± standard deviation (n=6) ………………………62

ix

1

CHAPTER 1. INTRODUCTION
Zwitterionic polymers are a unique type of polymers having an equivalent number of
homogenously distributed anionic and cationic groups on their polymer chains[1]. Common
zwitterionic polymers include poly(betaine) or poly(choline) carrying a positive and a negative
charge on the same monomer unit such as 2-methacryloyloxylethyl phosphorylcholine (MPC)[2],
sulfobetaine methacrylate (SBMA)[3], and carboxybetaine methacrylate (CBMA)[4]. There are
also a series of zwitterionic-like polymers prepared by copolymerization of monomers with
positive and negative charges at the ratio of 1:1 (For example, the monomers can be selected
from charged natural amino acids[5]), showing a similar property of zwitterionic materials[6]. The
highly soluble and neutral zwitterionic materials are known to provide strong hydration through
ionic solvation, forming a molecular level water layer to resist nonspecific binding and
attachment from proteins, blood, cells, and bacteria[7]. Such distinctive resistance is known as
non-fouling property, which is desirable in many scientific areas[8].
Based on the super-hydrophilic and non-fouling property of zwitterionic materials, they
have been widely involved to render excellent stealth properties to a variety of substrates of
different geometries, including decorating nano-sized carbon dots[9], and coating a flat
macroscopic surface, to resist protein binding and bacteria attachment[10]. The use of zwitterionic
materials for biological and medical applications has been considered promising. Recent studies
indicated that there was negligible foreign body reaction after implanting a zwitterionic
poly(carboxybetaine methacrylate) (PCBMA) hydrogel into the mice subcutaneously[11].
PCBMA hydrogel surface was also demonstrated to retain the stem cell phenotype and
multipotency, regardless the existence of differentiation-promoting media and cytoskeletal-
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manipulation agents[12]. This remarkable performance in interacting with host tissues or cells has
been attributed to the non-fouling nature of the zwitterionic materials.
The focus of this thesis is to explore two additional properties of these super-hydrophilic
zwitterionic polymers and take advantage of these properties in solving several challenges in the
drug delivery field.
(1) Capability to stabilize micelles constructed with zwitterionic polymers.
In the last decades, polymeric micelles have attracted considerable interest as drug delivery
carrier for a series of drugs, including low molecular mass hydrophobic drugs, proteins and
genes[13]. Typically, micelles would self-assemble into the macromolecular structure in an
aqueous environment and protect insoluble hydrophobic payloads in its hydrophobic core region.
Compared with other drug delivery strategies, such as liposomes, polymer or protein-drug
conjugates, polymeric nanoparticles, or pathogens[14], polymeric micelles show two significant
advantages: 1) Micelles have relatively small size. Hydrodynamic sizes of a micelle are usually
less than 50 nm[15]. Considering the dimensions of physiological pores in the body’s vasculatures
(e.g., kidney glomerulus pores, inter-endothelial junctions for healthy tissues, tumors, and
cancerous tissues), nanomedicine of smaller sizes (e.g., < 100 nm) is favored in blood circulation,
tissue penetration, and cellular uptake[16]. Recent evidence shows a sub-50 nm drug formulation
is desirable to achieve the collective outcome of deeper tumor tissue penetration and more
efficient cancer cell internalization, as well as a cellular response[14l,

17]

. Therefore, in vivo

circulation performance of encapsulated drugs could be drastically improved, leading to high
accumulation in the targeted site (e.g., tumor tissue) due to the enhanced permeability and
retention (EPR) effect[18]. 2) Feasibility to manufacture in large scale. Typically, the micelle is
the simplest assembled entity, with well-defined molecular structures and assembling behaviors.
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Such simple strucutre enables simple drug formulation and ease of manufacturing. Such
feasibility is vital since other advanced particle systems are complicated to prepare and have
built up obstacles for production in a stable and consistent manner. One notable example is the
PEGylated liposome with encapsulated doxorubicin (DOXIL®), which used to have a periodic
global shortage due to manufacturing issues[19]. In contrast, a micelle formulation is simple to
manufacture, such as Taxotere® or Taxol®, containing only the drug (docetaxel), the micelle
(polysorbate 80), and the solvent(alcohol);[20] can obtain fast FDA-approval; and be easily
manufactured on a large scale. With these appealing features, micelles are well accepted as a first
line technology to formulate drugs[13a]. Nevertheless, a fundamental limitation for micelles as
drug delivery carriers is their low stability to environmental changes, especially their
spontaneous dissociation at relatively low concentration. Once the concentration is below their
critical micelle concentration (CMC), micelle entities would disassociate into free surfactant and
cause a burst release of previously encapsulated drugs into the bloodstream. For example,
micellar drug Taxotere® was quickly removed from blood circulation once intravenously(i.v.)
injected[21]. This quick clearence can reduce the therapeutic performance of encapsulated drugs
and even cause toxicity concern[22]. Therefore, how to stabilize micelles, especially in
physiological conditions, is a challenge for drug delivery application.
In this dissertation, it is reported that zwitterionic Poly(carboxybetaine) (PCB) polymer
could conjugate with 1,2-distearoyl-sn-glycero-3-phosphoethanolamine (DSPE) lipid to form a
micelle with ultra-low CMC. A novel method was proposed to verify its ultra-low CMC and the
high stability in different media were also studied. The mechanism for zwitterionic PCB to
achieve ultra-low CMC property has been preliminarily explored. Details are described in
Chapter 2. Using melanoma as a tumor model, the antitumor performance of docetaxel
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encapsulated in DSPE-PCB micelle is described in Chapter 3 where enhanced antitumor
performance compared with control formulations, including the commercial Taxotere®, was
observed.
(2) Capability to improve the pharmacokinetics of proteins while mitigating the commonly
seen bioactivity loss.
Therapeutic protein drugs, such as insulin, have been used clinically for a long time. Using
polymers to modify a protein drug could effectively increase its circulating half-life in the
bloodstream, reduce the dosage required, and improved the therapeutic performance-- a
significant advantage for patients. Polymer-protein conjugation has been extensively explored in
the past decades and has shown the enhanced stability of the protein under storage, transport, and
other stresses[23]. For example, protein stability under lyophilization is significantly increased
after modification with polymers.[24] The most widely used conjugation strategy is called
PEGylation, by using polyethylene glycol (PEG) to conjugate proteins.[25] However, a major
problem with PEGylation, as well as conjugating with other common polymers, is the sacrificed
bioactivity of the conjugated protein.[26] Significant results indicate that conjugating PEG, and
other polymers as well, on proteins through conventional covalent coupling chemistry resulted in
polymer chains non-selectively attached on the protein surface groups (e.g., amines), and
potential attachment near to the protein’s active site significantly inhibited the protein from
performing designated biological function (e.g., amine group on Gly A1 of insulin)[27]. A much
higher dosage was required to reach the same therapeutic effect for the protein-drug with reduced
bioactivity and significantly compromised pharmacological activity. Compared with unmodified
native form, polymers modified protein drugs may demand high production costs and cause
long-term toxicity concerns due to the drastically increased working dose. We discovered that
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zwitterionic PCB-polymer-modified insulin did not show a significant reduction (student t-test)
of in vitro bioactivity compared with its native form. By improving the pharmacokinetics of
insulin while maintaining its bioactivity, PCB-insulin was found to show even higher blood
glucose lowering capability compared with native insulin in an animal study. PCB-insulin was
obtained via a simple conventional coupling chemistry and was expected to solve the bioactivity
loss issue in large. Details are described in Chapter 4.
Copyrights of texts and figures in this dissertation related to my publications were obtained
through copyright t© Spring Nature 2018 and copyright © John Wiley and Sons 2017.
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CHAPTER 2. DISCOVERY OF ULTRA-LOW CMC ZWITTERIONIC
MICELLES
A fundamental challenge for conventional micellar carriers is micelle systems disassemble
into free surfactants when diluted at concentrations below the critical micelle concentration
(CMC). Such premature disassemble limits the bioavailability in vivo of injected hydrophobic
drugs encapsulated in micellar systems. In this chapter, a novel micelle comprising a
superhydrophilic zwitterionic polymer domain and a superhydrophobic lipid domain is
introduced. Such a micelle was demonstrated to own an undetectable CMC below 10-6 mM, a
value that is orders of magnitude lower than the CMC (> 10-3 mM) of typical micellar systems.
In addition, when zwitterionic moieties or zwitterionic polymers were added into a micelle
solution, conventional micelle could be stabilized even at a concentration below their inherent
CMC.
2.1 Introduction
Micelles play a pivotal role in drug delivery[15, 22a, 28]. They are small sub-50 nm entities
physically assembled by water-soluble amphiphilic surfactants and can solubilize hydrophobic
drug molecules that are not well dissolved in water. Compared with other drug stabilizing or
delivery strategies (including from liposomes, polymer- or protein-drug conjugates and
polymeric nanospheres to cells or pathogens)[14a-k, 14m, 14n, 29], micelles have been received as the
first-line technology.[22a] Their molecular structures and assembling behaviors are well defined,
and a drug solution stabilized by micelles can be easily manufactured. These features enables
large scale production and stable clinical performance of the formulations. However, the main
challenge with micelles is that all conventional micelles, unless chemically crosslinked,[13b, 15, 22a,
28a]

will disassemble into free surfactants under diluted conditions (e.g., below critical micelle

concentrations, CMC, which is typical when infusing the micelle/drug formulation into the body).
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Drugs previously stabilized in the hydrophobic region of a micelle core will become insoluble
due to the loss of micelle structure. Such precipitation will severely reduce its bioavailability and
deteriorate its therapeutic performance.[22, 30] This challenge remained insurmountable since all
micelles have an apparent CMC and cannot keep stabilizing hydrophobic cargo when diluted at
concentrations below the CMC.[28b]
In this chapter, it is demonstrated that such stability challenge could be potentially solved
by a so-called “sharp polarity contrast” micelle system (Fig. 2-1). In this sharp contrast system,
each surfactant molecule comprises a super-hydrophilic zwitterionic polymer domain and a
superhydrophobic lipid domain. The polarity contrast between the two domains is drastically
“sharper” than most conventional micelle molecules. With an appropriate molecular weight
(MW) of zwitterionic polymers, such sharp-contrast micelles have an undetectable ultra-low
CMC below 2.7 x 10-6 mM. Such ultralow CMC for micelle is at least six orders of magnitude
lower than that for sodium dodecyl sulfate (SDS, CMC = 8.2 mM; commonly found in cleaning
and hygiene products) and four orders of magnitude lower than Polysorbate 80 (CMC = 0.012
mM; widely used to formulate drugs, e.g., chemo drug docetaxel under the trade name of
TAXOTERE®[31]). Even when a zwitterionic moiety or polymer was added into a micelle
solution (not chemically modifying the micelle), the existing micelle molecules in the new
solution were stabilized at concentrations below their inherent CMC. It is demonstrated that the
ultra-low CMC micelle could stabilize hydrophobic cargoes (without micelle dissociation) in
extremely diluted conditions (for example, < 10-3 mM), including clinically relevant dilution
conditions in serum in which conventional micelles failed to stabilize hydrophobic cargoes.
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2.2 Materials and Methods
2.2.1 Material
DSPE-PCB 2K, 5K, and 10K were synthesized and characterized following a previously
established method.[32] The molecular weight of N-hydroxysuccinimide ester (NHS)-PCB was
characterized via Waters Breeze 2 system gel permeation chromatography (GPC) with Waters
2414 reflex detector. The mobile phase was phosphate buffered saline (PBS) at a flow rate of 1
mL/min.

Polysorbate

80,

SDS,

CTAB,

HAuCl4,

NaBH4,

styrene,

divinylbenzene,

trifluoroethanol were obtained from Sigma-Aldrich. (St. Louis, USA). DSPE-PEG 5K was
obtained from Laysan Bio, Inc. (Arab, USA). Hexadecyltrimethylammonium bromide (CTAB),
(dodecyl

dimethylglycine)

CB12C,

n-Tetradecyl-N,

N-Dimethylglycine

(CB14C),

3-

(decyldimethylammonio) propane sulfonate (SB10C) and 3-(N, N-Dimethylpalmitylammonio)
propane sulfonate (SB16C) were obtained from Anatrace Product. LLC (Maumee, USA).
2.2.2 Preparation of gold nanoparticles (NPs) encapsulated by DSPE-PCB 5K
CMC for DSPE-PCB 5K (a zwitterionic carboxy betaine polymer (PCB) of 5000 Dalton
molecular weight (MW) conjugated to 1,2-distearoyl-sn-glycero-3-phosphoethanolamine (DSPE)
lipid) was determined via an established pyrene method.[33] During a typical “Dilutingconcentrating” method for CMC determination, a probe (< 5 nm) is first loaded into a micelle
core at high micelle concentration (> CMC). To load gold nanoparticle (NP) probe, micelles and
HAuCl4 are dissolved in 10 mL deionized water and vigorously stirred at room temperature,
followed by dropwise addition of 1 mL NaBH4 aqueous solution (micelle: Au: NaBH4 (molar
ratio) is typically 1:1:6). The solution turns red, and the stirring is kept for another 5 min. To
load cross-linked Polystyrene NP probe, micelles, photo-initiator 2959 (2-hydroxy-4'-(2hydroxyethoxy)-2-methyl-propiophe), styrene and divinyl benzene (molar ratio is typically
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1:10:1.5:1) are sonicated in deionized water to form nano-emulsion, followed by 20 min reaction
under UV light (365 nm). Micelles with either gold NP or PS NP loaded are further purified
through 10K MWCO ultrafiltration to remove rough materials forming the probes, and 0.2 μm
filter to remove unexpected large particles. The size of the probes can be determined by DLS
(Zetasizer Nano-ZS, Malvern Instruments) by taking the size difference between empty micelles
and loaded micelles. For gold NPs probe, its size can be additionally measured by the maximum
absorbance wavelength using a UV-visible spectrometer (Thermo Scientific Multiscan Go).
During the diluting-concentrating procedure for CMC determination, the liquid sample was not
further treated with filtration.
Aggregation Numbers (Nagg) of DSPE-PCB 5K micelles were calculated from the ratio of
an apparent molecular mass of the micelles which was measured via static light scattering (SLS),
and Mw for a single DSPE-PCB 5K chain. Apparent molecular masses of DSPE-PCB 5K
micelles was obtained by measuring a series of samples with different concentrations (from 1.2
g/L to 4.8 mg/L) using a Malvern Zetasizer Nano-ZS.
2.3 Results and Discussion
Sharp-contrast micelle-forming molecule DSPE-PCB 5K was synthesized following a
previous method,[32] and its structure is shown in Fig. 2-1 DSPE-PCB 5K powder is extremely
water-soluble, and its resulting micelles were imaged by transmission electron microscopy (TEM)
(Fig. 2-2a). The size of this micelle was measured by dynamic light scattering (DLS) (Fig. 2-2b)
to have a hydrodynamic diameter of 20±3.5 nm (mean ± stand deviation, N=3) in phosphate buffered saline (PBS). The hydrophobic core domain of DSPE-PCB 5K micelle was detected
using pyrene as reflected by the decrease in the intensity ratio of the first to the third highest
energy bands (I1/I3) in the emission spectra of pyrene from 1.7 in water to 1.1 in micelle solution
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(Fig. 2-3), following a previous method.[33] It should be noted that PCB such as 5K Dalton
molecule weight is extremely water soluble without forming particles or aggregates
(hydrodynamic diameter =3.7±1.0 nm). The aggregation number (Nagg) of DSPE-PCB 5K
micelle in water was 44.
The CMC for DSPE-PCB 5K was determined to be 1.3 x 10-3 mM using the pyrene probe
method (Fig. 2-4).[33] The pyrene method is one of the most sensitive and precise methods of
CMC determination.[34] However, it does not have sufficient sensitivity to measure a CMC below
10-3 mM[35] because the final concentration for pyrene is maintained at 6 x10-4 mM (in our
previous protocol as well as others[33, 36]) to give good quality fluorescent spectra. A micelle
concentration approaching or below 10-4 mM cannot significantly change the aggregation
behavior of pyrene, and potential micelle formation cannot be detected (as reflected by pyrene
spectrum change). As a consequence, 1.3 x10-3 mM as measured by the pyrene method is an
upper CMC estimation for DSPE-PCB 5K. There are other fluorescent dyes such as 2-ptoluidinylnaphthalene-6-sulfonate (TNS) and 1-anilinonaphthalene-8-sulfonate (ANS),[37] or
other ways to determine CMC including light and X-ray scattering,[38] surface tension study,[39]
and isothermal titration calorimetry.[40] None of those methods can precisely detect a CMC < 10-4
mM. Limited success in determining a CMC < 10-4 mM has been achieved by extrapolation of
CMC values of structurally-similar molecules[41] and through filtration of radioactively labeled
surfactants.[42] However, these approaches are not readily available.
To explore a potential CMC below 10-3 mM, a “diluting-concentrating” method was
developed. An initial stable colloid was prepared by reducing soluble Au3+ ions to insoluble gold
nanoparticles (NPs) in the presence of micelles at concentrations far above their CMCs. Small
gold NPs (< 5 nm) were formed as non-soluble probes and partitioned into the hydrophobic cores
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of stabilized micelles. The gold probe size was estimated from maximum absorbance peak of
gold NPs,[43] and also from the size increase from empty micelle to probe-loaded micelle
(measured by DLS). The micelle-protected gold NPs were subject to serial dilutions in water,
and extremely diluted micelle concentrations (10-6 mM) can be reached. Potential aggregation of
gold NPs resulted in an increase in both the hydrodynamic size of the colloid and the maximum
absorbance wavelength for gold NPs,[43] as measured by DLS and UV-spectroscopy, respectively.
Considering that the samples may be too dilute for these measurements, they were concentrated
using a rotary evaporator at 35 oC under reduced pressure and then re-measured for these
parameters. The aggregation of hydrophobic gold NPs cannot be reversed by this concentrating
process and was detected from their corresponding concentrated samples. Generally, once
hydrophobic gold NPs aggregated, they cannot be re-dispersed to their original size and sizedistribution, even with sonication. There is a possibility that DSPE-PCB 5K may be unique from
all the other surfactants in that it is capable of re-stabilizing the aggregated gold NPs upon
concentration. This possibility is excluded based on the following experiment: A polysorbate 80
protected gold NPs solution at micelle concentration of 2.1 mM had an initial hydrodynamic size
of 20.5 ± 3.2 nm (size of gold NPs). Then the solution was diluted with water to reach micelle
concentration of 0.0042 mM. To this solution, DSPE-PCB 5K was added to reach the
concentration of 0.0042 mM. The mixture was then condensed to the polysorbate 80
concentration of 2.1 mM which is above its CMC. If DSPE-PCB 5K could re-stabilizing the
aggregated gold NPs upon concentration, the size of gold nanoparticle after concentration should
be similar to the size before dilution. However, size of gold nanoparticle in this concentrated
mixture was measured to be 68.3 ± 7.5 nm, indicating that the previously aggregated gold NPs
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did not re-disperse. So DSPE-PCB 5K is not unique to re-stabilizing the aggregated gold NPs
upon concentration.
Since cargo aggregation is attributed to the dissociation of protecting micelles, this method
indirectly detects CMC values. A series of common micelles commercially available with known
CMCs labeled by the manufacturers were used to verify this method, including non-ionic
micelles

(polysorbate

80,

DSPE-PEG

5K

and

2K),

cationic

micelles

(hexadecyltrimethylammonium bromide (CTAB)), anionic micelles (sodium dodecyl sulfate
(SDS)), zwitterionic carboxy betaine and sulfobetaine micelles with varied hydrophobic chain
lengths (dodecyl dimethylglycine (CB12C), N-Tetradecyl-N-N-Dimethylglycine (CB14C), 3(decyldimethylammonio)

propane

sulfonate

(SB10C),

3-(N,N-

Dimethylpalmitylammonio)propane sulfonate (SB16C)). Representative measuring curves are
shown in Fig.2-5. Measuring curves for all samples tested are shown in Fig. 2-6. Without
exception, CMC values for all micelles are right positioned at a concentration, below which both
the hydrodynamic size of the colloid and the maximum absorbance wavelength for gold NPs
start to increase significantly (Student’s t-test, p < 0.05). Similar to common probes for CMC
determination (for example, pyrene and other dye molecules and so on.), the presence of gold
NPs in the hydrophobic micelle core does not seem to influence the dissociation behavior of
micelles. If it did, an artefact signifying that the colloid system does not aggregate below the
CMC would appear.
DSPE-PCB 5K has an undetectable ultra-low CMC. Using the validated “dilutingconcentrating” method, DSPE-PCB 5K micelle protected gold NPs do not show signs of cargo
aggregation at a concentration as low as to 2.7 x 10-6 mM (Fig. 2-5; no significant signal increase
based on Student’s t-test). Their CMC is considered ultra-low and below our current detection

13

limit of 2.7 x 10-6 mM. The detection limit can potentially be lowered by one order of magnitude
by further diluting the micelles (for example, into a 10 L container), then concentrating 1.0 -1.5
L each time (using the current 2 L evaporation flask). This approach is laborsome and has little
room to further lower the CMC detection limit. In contrast, DSPE-PEG 5K micelles, widely used
to construct nanomedicines, have an apparent CMC about 1 x 10-3 mM, consistent with literature
values[35, 44], and dissociate at concentrations, at least, three orders of magnitude higher than
DSPE-PCB 5K. Compared with DSPE-PCB 5K, which has multiple zwitterionic CB moieties as
the polar group, CB14C contains only one zwitterionic carboxy betaine and has higher CMC at
3.4 x 10-2 mM. To confirm that DSPE-PCB 5K has an ultra-low CMC, following experiments
were performed: 1) Gold NP colloids were formed in the presence of PCB 5K replacing DSPEPCB 5K and were found to be unstable (aggregate). Note that DSPE-PCB 5K/gold colloid was
stable at room temperature for weeks without precipitation. This control experiments excludes
the possibility of PCB tightly interacting with gold NPs, preventing dissociation of DSPE-PCB
5K micelles (an artifact of lowered CMC). 2) Gold NP probes were replaced by cross-linked
polystyrene (PS) NP probes. Following the same “diluting-concentrating” method, where colloid
aggregation was detected by DLS, CMC results were obtained similarly to Fig. 2-5a, regardless
of the probe used (Fig. 2-6). It should be noted that both gold and crosslinked PS NPs are not
soluble under extremely diluted conditions (10-6 mM). This insoluble property is the key to
obtaining reliable CMC results. Soluble salt NPs (e.g., CaCO3) were not found to work as probes
since they are released from the micelle at a diluted concentration below their water solubility
and aggregated when concentrated to the concentration above their water solubility (Fig. 2-7). 3)
DSPE-PCB 5K micelles at an extremely low concentration (2.7 x 10-6 mM) have been observed
using TEM (Fig 2-8).
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Zwitterionic PCB and its amount are critical to achieving ultra-low CMC property.
To explore the unique role of zwitterionic PCB in contributing to ultra-low CMC property,
conventional micelles (i.e., SDS and Polysorbate 80) were incubated either the free form of the
CB moiety or PCB 5K (with multiple CB) at high concentration (500 mg/mL for free form
carboxybetaine moiety and 80 mg/mL PCB) and found that conventional micelles were
stabilized in both cases (Fig. 2-9a, b and Fig. 2-10a, b). It should be noted that similar
stabilizing effects have been found in both inorganic and organic salt solutions.[45] We attribute
this effect to the super-hydrophilicity of CB and PCB (similar to salts), which increases the
polarity of the aqueous phase,[32, 46] strengthens the hydrophobic-hydrophobic interactions and
drives micelle assembly at concentrations far below inherent CMC. The presence of ethylene
glycol oligomer (OEG) or polymer (PEG), in contrast, increased the CMC for conventional
micelles (Fig. 2-9a, b and Fig. 2-10a, b), which is consistent with the literature.[47] OEG and
PEG are known for their hydrophobic nature and tend to decrease the polarity of the aqueous
environment,[32, 46] behaving the opposite to super hydrophilic CB and PCB. OEG and PEG are
typical water-soluble materials, and in some cases, their hydrophobic nature has been overlooked.
They should be strictly considered as amphiphilic materials since they can be dissolved in both
water and organic solvents such as dichloromethane. Zwitterionic polymers, by contrast, can be
dissolved in water but can be hardly dissolved in most organic solvents and are generally
considered to be superhydrophilic. Because of the polarity difference, PEG and zwitterionic
polymers have shown opposite effects such as in stabilizing lipid membrane[48], and avoiding
interaction with protein active center so as to reduce bioactivity loss of polymer-protein
conjugates[49]. The micelle stabilizing effect of CB or PCB 5K at a series of concentrations were
further examined. It was found that a minimum of roughly 200 mg/mL CB and 40 mg/mL PCB
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5K were required to prevent the dissociation of conventional micelles, e.g., SDS and Polysorbate
80 (Fig. 2-10c, d, e, f). Thus, the presence of zwitterionic CB moieties as polar groups for
DSPE-PCB 5K appears to be the key to the ultra-low CMC property.
In addition, it was found that an appropriate molecular weight (MW) of PCB (amount of
CB moieties per polymer) is critical for DSPE-PCB to achieve the lowest possible CMC (Fig. 29c, d). PCB MW is expected to be as high as possible to ensure the CMC lowering effect.
However, PCB MW should not be too large since micelles with longer hydrophilic polymer
chains typically have high CMCs (e.g., shown by hydrophilic polyvinylpyrrolidone (PVP)hydrophobic alkyl chain micelles[35]). It appears that DSPE-PCB 5K has a the balanced PCB
MW and achieves the lowest possible CMC (< 10-6 mM (undetectable)) compared with DSPEPCB 2K (CMC = 1.2 - 6 x 10-5 mM) and 10K (CMC = 0.9 - 1.8 x 10-5 mM), and other reported
micelles containing zwitterionic polymer blocks.[50]
One major challenge with drug delivery is the dissociation of carrier entities (e.g., micelles)
as they are infused into the blood stream since the drug carrier is typically diluted below its CMC.
Blood serum comprises a large number of proteins (albumin) that decompose micelles and bind
with this surfactants.[51] Compared with water, dilution in serum is even more challenging for
assembled carrier systems. Here the stability of ultra-low CMC and conventional micelles in
fetal bovine serum (FBS) using the gold NP probes at 0.055 mM micelle concentration was
tested. (Fig. 2-11). It was found that DSPE-PCB 5K (ultra-low CMC) showed excellent stability
over 72 h. Conventional Polysorbate 80 and DSPE-PEG 5K micelles were not stable; for DSPEPEG 5K, it dissociated at this concentration even above its CMC. The diluted micelle
concentration tested (10-2 mM) is chosen by considering the situation of a 60 kg adult patient
having 4.5 L blood receiving 75 mg/m2 TAXOTERE® to treat breast cancer.[52] The hypothetical
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maximum micelle concentration (i.e. Polysorbate 80) in the blood is calculated to be 5.5 x 10-2
mM, assuming all drug was injected simultaneously. The reality is TAXOTERE® has to be
mixed with infusion saline and be slowly infused (typically complete in one hour).[53] As drugs
gradually enter the blood, they are immediately diluted, with micelle concentration lower than
10-2 mM. The serum stability test at 10-2 mM indicates that ultra-low-CMC micelles are more
stable than conventional ones as drug carriers at clinic-relevant concentrations.
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Figure 2-1 Ultra-low-CMC micelles and their unusual ability to stabilize cargoes in extremely
diluted conditions with micelle concentrations far below CMCs of common micelles. Conventional
micelles dissociate at a concentration below CMC, and thus cannot stabilize hydrophobic cargo. Structure
for ultra-low-CMC micelles is shown. For conventional micelles, polar groups are either non-ionic (e.g.,
polysorbate 80, having hydrophobic nature) or only contained one ionic group (e.g., sodium dodecyl
sulfate). Sharp-contrast micelles with multiple polar zwitterionic (polyzwitterionic) groups were recently
reported[32].
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Figure 2-2 TEM and DLS data of DSPE-PCB 5K micelle. a, Representative TEM image for DSPEPCB 5K micelle (5 mM) in water taken by JEOL 2010 Transmission electron microscopy. Stained with 2%
uranyl acetate. The scale bar in the figure is 50 nm. b, DLS data for DSPE-PCB 5K in PBS (0.5 mM),
showing an average diameter of 20 ±3.5 nm (mean ±SD, N = 3) with a polydispersity index of 0.13.
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Figure 2-3. The hydrophobic core domains of DSPE-PCB 5K micelles were detected using pyrene as
reflected by the decrease in the intensity ratio of the first to the third highest energy bands (I1/I3) in the
emission spectra of pyrene from 1.7 in water (a) to 1.16 in 0.17 mg/mL micelle in water (b). The
excitation wavelength was 334 nm.
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Figure 2-4. The CMC of DSPE-PCB 5K was determined to be 1.3 x 10-3 mM using the pyrene probe
method (mean ±SD, N=3).
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DSPE-PEG 2K. Non-ionic surfactant. CMC (from ref.[44a]) = 0.5-1 x10-3 mM
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SDS. Anionic surfactant. CMC (provided by manufacturer) = 8.2 mM
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g)

CB14C. A zwitterionic surfactant with single carboxy betaine as a hydrophilic group and
14 carbon chain as a hydrophobic group. CMC (provided by manufacturer) = 0.034 mM
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i)

SB16C. A zwitterionic surfactant with single sulfobetaine as a hydrophilic group and 16
carbon chain as a hydrophobic group. CMC (provided by manufacturer) = 0.01~0.06 mM
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Figure 2-6. “Diluting-concentrating” method to determine micelle CMCs using gold NPs as a probe.
Measuring curves for all samples tested are shown (a-j), including non-ionic, cationic, anionic, and
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zwitterionic surfactants. Aggregation of the gold probe at different micelle concentrations was reflected
by the hydrodynamic size of the colloid and gold maximum absorbance wavelength (mean ± SD, N=3).
Known CMC values for micelles were listed and indicated by dashed arrows. The current “dilutingconcentrating” method is able to detect a CMC as low as 2.7 x 10-6 mM.

a)

b)

Figure 2-7. CaCO3 probes were encapsulated in DSPE-PCB 5K micelle, by dissolving micelles and
CaCl2 in 10 ml deionized water followed by dropwise addition of 1 mL Na2CO3 aqueous solution under
vigorous stirring at room temperature for 15 min (micelle:CaCl2:Na2CO3 (molar ratio) = 1:1:1). (a) The
size of DSPE-PCB 5K/CaCO3 nanoparticles before dilution. Micelle concentration was 3 mg/mL (0.5
mM), and CaCO3 concentration was 0.05 mg/mL (0.5 mM). (b) The size of DSPE-PCB 5K/CaCO3
nanoparticles after 1000-fold dilution to micelle concentration of 5 x 10-7 M, and CaCO3 concentration of
0.05 mg/L, and then concentrated back to the original concentration at (a). The solubility of CaCO3 in
water is 0.013 mg/mL or 13 mg/L. The concentration of CaCO3 encapsulated in micelle before dilution
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(0.05 mg/mL) was above its solubility (0.013 mg/mL), and the concentration of CaCO3 encapsulated in
micelle after dilution (0.05 mg/L) was below its solubility (13 mg/L). CaCO3 was found to be released at
diluted concentration and aggregated into large particles after condensation as shown at (b).

Figure 2-8. TEM figures of DSPE-PCB 5K micelle at an extremely low concentration (2.7 × 10-6 mM).
Stained with 2% uranyl acetate. The scale bar in the figure is 20 nm.

27

b

540

SDS
SDS+ CB
SDS+ OEG

535

Maxium Absorbance Peak(nm)

Maxium Absorbance Peak(nm)

a

530
525
520
515

530

Polysorbate 80
Polysorbate 80 + CB
Polysorbate 80 + OEG

525
520
515
510
505

510
1

10

0.01

Concentration of SDS(mM)

d

560

DSPE-PCB 2K
DSPE-PCB 5K
DSPE-PCB 10K

550

1

140

DSPE-PCB 2K
DSPE-PCB 5K
DSPE-PCB 10K

120
Average Size (nm)

Max. Absorbance Peak (nm)

c

0.1

Concentration of Tween(mM)

540
530
520
510

100
80
60
40
20

1E-5

1E-4

1E-3

0.01

0.1

1

Concentration (mM)

1E-5

1E-4

1E-3

0.01

0.1

1

Concentration (mM)

Figure 2-9 Effect of supplying zwitterionic moieties on the CMCs of conventional micelles, and
impact of the zwitterionic PCB MW on the CMC of DSPE-PCB. a,b, Gold NPs were loaded in SDS
(a) and Polysorbate 80 (b), and upon water dilution, their aggregation behavior (due to micelle
dissociation) was measured by the increase in maximum absorbance peak of gold (mean ± SD, N=3).
When 500 mg/ml CB was used as dilution solvent, no significant gold aggregation was observed in the
dilution range, indicating a stabilized micelle (despite a concentration below its inherent CMC). In
contrast, when 500 mg/mL OEG was used as dilution solvent, there was gold NP aggregation at high
micelle concentrations, showing an increase of micelle CMC. CB and OEG alone (without the aid of
micelles) cannot stabilize gold NPs, leading to aggregation. It should be noted that DLS data are not
reliable in this experiment since the large concentration of small-sized CB or OEG moieties interferes
with the hydrodynamic size readings for aggregated gold NPs. c, d, “Diluting-concentrating” method to
probe CMCs for DSPE-PCB 2K, 5K, 10K micelles. Aggregation of the gold probe at different micelle
concentrations was reflected by the gold maximum absorbance wavelength (c) (mean ± SD, N=3) and the
hydrodynamic size of the colloid (d) (mean ± SD, N=3). CMC values were determined for DSPE-PCB
2K and 10K and are indicated by dashed arrows.
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Figure 2-10. Gold NPs were loaded in SDS (a) and Polysorbate 80 (b), and upon water dilution,
their aggregation behavior (due to micelle disassociation) was measured by the increase in
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maximum absorbance peak of gold (mean ± SD, N=3). When 100 mg/mL PCB polymer (MW=
5K) was used as dilution solvent, no gold nanoparticle aggregation was observed in the dilution
range, indicating micelles were stabilized even at a concentration below its inherent CMC. In
contrast, when 100 mg/mL PEG polymer (MW= 5K) was used as dilution solvent, there was
gold NP aggregation at the concentrations above the inherent CMC of micelles. PCB and PEG
alone (without the aid of micelles) cannot stabilize gold NPs, leading to severe aggregation. It
should be noted that DLS data are not reliable in this experiment since the presence of a large
concentration of small size PCB or PEG interferes with the hydrodynamic size reading for the
aggregated gold NPs. Different concentration of PCB solutions was used as dilution solvent, and
within the concentration series, 40 mg/mL PCB was the minimum required to stabilize (c) SDS
and (d) Polysorbate 80 upon dilution (mean ± SD, N=3). Different concentrations of CB
solutions were used as dilution solvents, and within the concentration series, 200 mg/mL CB was
the minimum required to stabilize (e) SDS and (f) Polysorbate 80 upon dilution (mean ± SD,

Max. Absorbance Peak (nm)

N=3).
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Figure 2-11 Stability of ultra-low-CMC micelle and conventional micelles with gold NP probes
encapsulated at 5.5 ×10-2 mM micelle concentration in 100% fetal bovine serum (FBS) over 72 h at room
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temperature. Potential micelle disassociation resulted in gold NP aggregation, which was measured by
gold maximum absorbance peak (mean ± SD, N=3). Known CMC values for each micelle are indicated
inside the graph.
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CHAPTER 3 THERAPEUTIC PERFORMANCE OF DRUG/DSPE-PCB 5K
FORMULATION
Commercially available micelle drug formulations, such as Taxotere®, usually have
stability issue and prematurely release drug when infused into the blood stream due to the high
CMC values of the micelles being used. The previous Chapter described a novel zwitterionic
micelle DSPE-PCB 5K with ultra-low CMC feature and demonstrated its stability in FBS over
72 hours at a clinically relevant condition. Therefore, it is of interest to evaluate the therapeutic
performance of such ultra-low CMC micelles as drug delivery carriers. In this chapter, a
docetaxel/DSPE-PCB 5K formulation was prepared via thin film hydration method using the
ultralow CMC micelle introduced in chapter 2. This new formulation was expected to show
better performance due to the high stability of ultralow CMC zwitterionic micelle. To evaluate
the anti-tumor performance of such new formulation, a melanoma tumor model on mice was
developed. Ultralow CMC micelles encapsulating docetaxel showed full elimination of tumors,
whereas conventional docetaxel micellar formulations did not reverse tumor growth. Ultralow
CMC micelles might become next-generation carriers for drug delivery.
3.1 Introduction
A well-known micelle based drug formulation is Taxotere®, a chemotherapy medication
used to treat a number of types of cancers. One single-dose vial of Taxotere® contains the active
ingredient docetaxl, polysorbate 80 micelle molecule and anhydrous ethanol. Clinically, this
formulation required dilution in 250 mL infusion bag containing 0.9% sodium chloride or 5%
dextrose and was then slowly infused into the blood stream which lasted for 1 hour. There are
two limitations for this formulation: 1) Fully prepared Taxotere infusion solution, the diluted
form, should be used within 4 hours including the 1 hour i.v. adinistration due to the low stability
of the micelle formualtion. 2) When infusing into the blood, the concentration of polysorbate 80
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(<< 5.5 × 10-2 mM) is much lower than its CMC value (0.012 mM). At such low concentration,
polysorbate 80 would disassemble into free surfactants and cannot stabilize and carry docetaxel
for blood circulation. In Chpater 2, zwitterionic micelle DSPE-PCB 5K was demonstrated to
have an ultralow CMC value and showed high stability in clinical-relavant environment.
Therefore, a new docetaxel formulation was prepared using zwitterionic micelle, and its
therapeutic outcome was examined by intravenously injecting to mice inoculated with melanoma
tumor (B16F10). Melanoma is a challenging disease to treat due to the well-documented chemoresistance[54]. Docetaxel was not clinically used to treat melanoma, but had been explored to treat
melanoma in animal studies through nanoparticle mediated delivery, though with marginal
improvement of the therapeutic outcome[55]. Considering the advantage of the ultralow CMC
zwitterionic micelle, it is curious to know if the new micelle formulation of the old drug can
enhance therapeutic treatment of melanoma in animal studies.
3.2 Materials and Methods
3.2.1 Materials
Docetaxel was obtained from LC Laboratories (Woburn, USA). B16F10 cells were
obtained from ATCC. Trifluoroethanol, Phosphate-Buffered Saline tablets, and acetonitrile (LC
grade) were purchased from Sigma-Aldrich (St. Louis, USA). RPMI 1640 medium was
purchased from Gibco (Dublin, Ireland).

3.2.2 Preparation of docetaxel/DSPE-PCB 5K formulation
To prepare docetaxel/DSPE-PCB 5K formulation, 150 mg of DSPE-PCB 5K and 6 mg
docetaxel were co-dissolved in 5 mL trifluoroethanol in a round-bottom flask. The solvent was
evaporated by rotary evaporation to obtain a thin film. The film was kept in a vacuum for 2 hours
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at room temperature to remove the residual trifluoroethanol. After the addition of 3 mL saline
and stirring at 800 rpm for 30 min, a transparent micelle solution with docetaxel loaded was
obtained. Docetaxel/DSPE-PEG 5K and docetaxel/Polysorbate 80 formulations were prepared
following the same procedure. Taxotere was prepared following a reference procedure[52-53, 56].
The weight ratios of the drug over surfactant for all formulations were kept at 4%, which is the
drug loading level for TAXOTERE®[57].
Drug release profiles were determined by placing 100 μL different formulations into SlideA-Lyzer MINI dialysis microtubes (3500 Da MW cutoff) and dialyzed against PBS at 37 oC with
gentle stirring. At different time intervals, docetaxel remained in the dialyzer was quantified
through HPLC by a Waters Breeze 2 System equipped with a Waters 2998 photodiode array
detector at 230 nm and a Waters Symmetry C18 column (4.6 × 7.5 mm). The mobile phase was a
mixture of acetonitrile/water (50:50 volume/volume) at a flow rate of 1 mL/min. The docetaxel
showed a single elution peak at 5.47 min.

3.2.3 Animal Experiments
The animal experiment was approved by the Institutional Animal Care and Use Committee
(IACUC) of Wayne State University, and performed in compliance with relevant laws and
institutional guidelines. B16F10 cells (ATCC, CRL-6475) were cultured in RPMI 1640 medium
containing 10% fetal bovine serum at 37 oC under a 5% CO2 atmosphere. For in vivo tumor
therapeutic studies, healthy C57BL/6 mice (7 weeks old, 20-25 g) received a subcutaneous
injection of 100 μL B16F10 cells (5 × 106 cells/mL) in the right flank. After 8 days of inoculation,
the tumor became visible, and different formulations were administered by intravenous injection
via tail vein 5 times every other day at the dosage of 10 mg docetaxel/kg body weight. The tumor
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volume of the mice was measured day by day and calculated with an equation of (L×W 2)/2
where L is the long length, and W is the short length of the tumor. Mice were euthanized if their
weight loss exceeded 15% or if their tumor grew to a volume greater than 1000 mm3. For
maximum tolerated dose (MTD) study, healthy C57BL/6 mice received one intravenous
injection of different docetaxel formulations through the tail vein at the dose of 25 mg/kg, 40
mg/kg, or 55 mg/kg. Treated mice were subsequently observed day by day and checked for
mortality, body weight, and signs of toxicity. To measure docetaxel concentration in plasma,
healthy C57BL/6 mice (7 weeks old, 20-25g) were treated with intravenous injection via tail vein
at the dosage of 10 mg/kg. At different time intervals, 50 µL blood samples were collected and
transferred to sodium heparin treated tubes. Docetaxel was extracted from the plasma
supernatant with ethyl acetate, and the extracted solution was evaporated under a gentle stream
of nitrogen. The extraction residues were reconstituted in the mixture of acetonitrile/water (50:50
volume/volume). The docetaxel concentration was measured using HPLC as mentioned above.
To test bio-distribution, healthy C57BL/6 mice (7 weeks old, 20-25 g) received a
subcutaneous injection of 100 µL B16F10 cells (5 × 106 cells/mL) in the right flank. After 8 days
of inoculation when tumors became visible, different formulations were administered by
intravenous injection via the tail vein. Mice were euthanized at the certain time point. Organs
(liver, heart, kidney, spleen, lung and tumor tissues) were collected, thoroughly washed with
saline (0.9% NaCl), weighted, and stored for further analysis. Organs or tissues were
homogenized with Mini-beadbeater-24 (Biospec Products, Inc., USA) in acetonitrile/water
(50:50 volume/volume). The resulting 200 µL samples of homogenized tissue were mixed with 1
mL ethyl acetate. Well-mixed samples were then centrifuged at 4000 g for 5 minutes. The
organic layer was transferred to a clean tube and evaporated under a gentle stream of nitrogen.
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The extraction residue was reconstituted in 1 mL mixture of acetonitrile/water (50:50
volume/volume). The docetaxel concentration was measured using HPLC.
3.3 Results and Discussion
To study the applicability of using ultra-low CMC micelles to deliver real drugs, antitumor drug docetaxel was chosen and docetaxel/ DSPE-PCB 5K formulation was prepared using
a simple thin-film hydration method (see Experimental Section)[57-58]. Control formulations
include docetaxel/Polysorbate 80 and docetaxel/DSPE-PEG 5K, similarly made through thinfilm hydration method, and Taxotere® formulated based on literature reports[52-53, 56]. The weight
ratios of the drug over surfactant for all formulations were kept at 4%, which is the drug loading
level for Taxotere®[57]. The hydrodynamic diameters for all tested samples were around 22 nm
as determined by DLS. However, after diluting these samples in FBS to reach micelle
concentration of 5.5 × 10-2 mM (the hypothetical maximum micelle concentration in the blood),
only docetaxel/ DSPE-PCB 5K can maintain its hydrodynamic size, while all other control
formulations appeared to be unstable over the tested time period (Fig. 3-1). Drug release profiles
were determined by placing the formulations into Slide-A-Lyzer MINI dialysis microtubes
(3500Da MW cutoff) and dialyzed against PBS at 37 oC with gentle stirring. Docetaxel remained
inside the dialysis tubes at different time points was quantified using HPLC to calculate drug
release. DSPE-PCB 5K showed the highest retention of docetaxel compared with other control
micelles, with 50% drug released in 3.7 h (Fig. 3-2). The drug release mechanism in
docetaxel/DSPE-PCB 5K formulation is expected to be based on drug dissolution or drug
leaching. This has been indicated by the control study showing the zwitterionic micelles can
stabilize non-dissolvable gold NPs and crosslinked PS NPs but not soluble CaCO3 NPs at low
concentrations (5 × 10-4 mM). The stability of different docetaxel formulations after
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lyophilization was further checked. Results indicated that after lyophilization docetaxel/DSPEPCB 5K maintained its original hydrodynamic size, while all control micelle formulations
aggregated (Fig. 3-3).
The maximum tolerated dose (MTD) of docetaxel/ DSPE-PCB 5K was determined using
healthy C57BL/6 mice to be 55 mg docetaxel/kg body weight, significantly higher than control
formulations docetaxel/DSPE-PEG 5K (40 mg/kg), docetaxel/Polysorbate 80 (40 mg/kg), and
Taxotere® (25 mg/kg) (Fig. 3-4). To examine the antitumor activity of different
docetaxel/micelle formulations, C57BL/6 mice were inoculated with B16F10 cells in the right
flank. On day 8 after inoculation, they received an intravenous injection of one of the drug
formulations, followed by 4 more every other day. The dose for all drug/micelle formulations
was 10 mg docetaxel/ kg body weight. Docetaxel/DSPE-PCB 5K showed significantly better
anti-tumor activity compared with all other micellar docetaxel formulations, including
Taxotere® (Fig. 3-5a). All tumors treated with this formulation were eliminated by day 33 after
the first treatment, without recurrence over the 70 days observation period after tumor
inoculation (Fig. 3-5b and Fig. 3-5c). None of the control formulations based on docetaxel were
able to fully inhibit the melanoma tumor. In fact, it is rare for any chemotherapy drugs to
completely eliminate melanoma[31c, 59].
To further investigate the in vivo circulation profile of docetaxel/DSPE-PCB 5K, different
docetaxel formulations were injected intravenously to healthy C57/BL6 mice. At different time
points, blood samples were collected, and the concentration of docetaxel in plasma was
measured via HPLC. It was found that docetaxel/DSPE-PCB 5K showed longer blood
circulation than all other micellar docetaxel formulations (Fig. 3-6). The α and β half-life of
docetaxel/DSPE-PCB 5K were calculated to be 0.6 hours and 5.9 hours, while for
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TAXOTERE® these values were 4 min and 36 min, respectively. For bio-distribution, healthy
C57/BL6 mice were treated with intravenous injection of different docetaxel formulations after
inoculation of B16F10 cells. Bio-distribution of docetaxel at different time points has been
further studied. Significantly higher tumor accumulation of docetaxel/DSPE-PCB 5K was
observed at 24 hours post-injection compared with control formulations (Fig. 3-7). Such
enhanced drug accumulation to tumor site has been observed at as early as 2 hours after
administration (Fig. 3-8). The antitumor performance of docetaxel/DSPE-PCB 5K formulation
was attributed to the stabilization ability of the ultra-low CMC micelle which improved the blood
circulation and drug accumulation in tumor.
In summary, the ultra-low CMC zwitterionic micelle was used to prepare a new
formulation of docetaxel. Therapeutic performance was evaluated on a melanoma model and
compared with Taxotere and other controls. Results showed that the docetaxel/ ultra-low CMC
micelle formulation can completely eliminate the melanoma tumor on mice, while the control
formulations, including TAXOTERE®, was unable to do so. Excellent therapeutic performance
was attributed to the ultra-stability in protecting cargoes without dissociation. Therefore, it is
expected the ultra-low CMC micelle can be utilized to enhance the delivery and therapeutic
effects of other drugs in general.
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Figure 3-1. Stability of different docetaxel formulations diluted in FBS (mean ±SD, N=3).
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Figure 3-2. The release profile of different docetaxel formulations in dialysis against PBS. (mean ±SD,
N=3)
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Figure 3-4. Dose escalation in healthy mice. Solutions of different formulations a, Taxotere; b,
docetaxel/DSPE-PCB; c, docetaxel/DSPE-PEG; d, docetaxel/Polysorbate 80 were administered through
intravenous tail vein injection. (mean ±SD, N=3).
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Figure 3-5. (a)Anti-tumor performance of docetaxel/DSPE-PCB 5K formulation (mean ± SD, N = 7)
compared with other formulations (mean ± SD, N = 7). On day 10 after treatment (*), a Mann-Whitney
Test indicated that docetaxel/DSPE-PCB 5K delayed the tumor growth greater than all other four controls
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Figure 3-7. Bio-distribution of different docetaxel formulations at 24 hours post i.v. injection (mean ±SD,
N= 4). One-Way ANOVA analysis with Bonferroni multi-comparison: significant difference between
docetaxel/DSPE-PCB

5K

and

docetaxel/DSPE-PEG

5K,

docetaxel/DSPE-PCB

5K

and

docetaxel/Polysorbate 80, docetaxel/DSPE-PCB 5K and Taxotere, at p < 0.001 (***), p < 0.0001 (****),

a)

D o c e t a x e l C o n c e n t r a t io n (  g /g )

and p < 0.0001 (****), respectively.

T a x o te re
10

2 hour

P C B -D S P E
P E G -D S P E
P o ly s o r b a t e 8 0

5

0

K id n e y S p e e n L iv e r

Lung

H e art T u m o r

D o c e t a x e l C o n c e n t r a t io n (  g /g )

b)
20

8 hour

T a x o te re
P C B -D S P E

15

P E G -D S P E
P o ly s o r b a t e 8 0

10

5

0
K id n e yS p le e n L iv e r

Lung

H e art T u m o r

Figure 3-8. Bio-distribution of different docetaxel formulations. a, bio-distribution of docetaxel from
different formulations at 2 hours post i.v. injection (mean ± SD, N= 4). One-Way ANOVA analysis with
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No significant difference between docetaxel/DSPE-PCB 5K and docetaxel/DSPE-PEG 5K. b, biodistribution of docetaxel from different formulations at 8 hours post i.v. injection (mean ± SD, N= 4).
One-Way ANOVA analysis with Bonferroni multi-comparison: significant difference between
docetaxel/DSPE-PCB

5K

and

docetaxel/DSPE-PEG

5K,

docetaxel/DSPE-PCB

5K

and

docetaxel/Polysorbate 80, docetaxel/DSPE-PCB 5K and Taxotere, at p < 0.01, p < 0.0001, and p < 0.001,
respectively.
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CHAPTER 4. SIMPLE PROTEIN MODIFICATION USING
ZWITTERIONIC POLYMER
In this chapter, it is demonstrated that when the zwitterionic carboxybetaine polymer
(PCB) was conjugated to insulin through simple conventional coupling chemistry, the resulting
PCB-insulin did not show a significant reduction of in vitro bioactivity. The reported simple
strategy of using PCB for protein conjugation is expected to solve the bioactivity loss issue for
most protein-polymer conjugations. The obtained PCB-insulin shows two significant advantages
as a novel pharmaceutical agent. First, for PCB-insulin, in vivo pharmacological activity of
lowering blood glucose was increased compared with native insulin. Such increase is expected to
be due to both the improved pharmacokinetics and retained bioactivity of PCB-insulin. Second,
its production is simple from manufacturing standpoints. The conjugation procedure involves
only one-step coupling reaction and does not require a site-specific linkage technique. The
synthesized PCB-insulin conjugates do not need chromatographic separation to purify. These
two advantages are expected to be translated to other types of therapeutic proteins as well.

4.1 Introduction
The major purpose of polymer-protein conjugation is to improve pharmacokinetics
(PK) and retain bioactivity in order to improve the pharmacological activity (the inherent
capacity of drug to alter chemical or physiological functions of a cell, tissue organ or
organism) of a modified protein.[60] The most widely used conjugation strategy is
PEGylation that uses polyethylene glycol (PEG) to conjugate proteins.[25] Despite
improved PK, PEGylation is known for its sacrificing the conjugated protein activity. [26]
Results indicate that conjugating PEG, and other commonly seen polymers as well, on
proteins through conventional covalent coupling chemistry resulting in polymer chains
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non-selectively attached on the protein surface groups (e.g., amines), and potential
attachment near a protein’s active site inhibit the protein from performing designated
biological function (e.g., amine group on Gly A1 of insulin) [27]. There are alternative
methods allowing for site-specific conjugation to proteins, e.g., involving re-engineering
the proteins, or laborsome separation, but those procedures are complex.[61] When PEG is
conjugated to proteins in a site-selective manner, however, the resulting PEG-proteins are
still subject to bioactivity loss. Eli Lily has developed a PEGylated insulin Lispro
(LY2605541) where a 20 kDa PEG was conjugated at the amino group of Lys B28 of
insulin Lispro. For LY2605541, a high molar concentration is still required to achieve
comparable glucose lowering effect to the unconjugated insulin as observed in the in vitro
insulin receptor binding studies.[62]
In this chapter, it is reported that the conjugation of zwitterionic carboxybetaine
polymer (PCB) on insulin through conventional coupling chemistry improves the PK of
the protein, but does not compromise the insulin in vitro bioactivity. Remarkably, this
conjugation strategy increases the in vivo glucose lowering activity for ~24% compared
with native insulin at equal molar dose when intravenously (i.v.) injected. In addition, the
synthesis of PCB-insulin does not require complicated site-specific linkage technique and
can be implemented through a simple one-step coupling reaction. The resulting PCBinsulin conjugates do not require chromatographic separations to obtain purified isoforms,
potentially enabling a simplified scaling-up, and manufacturing procedure.

4.2 Materials and Methods
4.2.1 Materials
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Human recombinant insulin was purchased from Life Technologies Corporation.
Methoxypolyethylene glycol 5000 Da acetic acid N-succinimidyl ester (PEG-NHS),
streptozotocin (STZ), Cu(I)Br, and all necessary solvents were purchased from Sigma-Aldrich.
HEPES buffer was purchased from Hyclone.
4.2.2 Synthesis of PCB-(N-hydroxysuccinimide) (NHS)
PCB-NHS was synthesized based on a previous procedure.[32] Briefly, NHS-PCB-tBu was
firstly synthesized through atom transfer radical polymerization (ATRP) of 2-tert-Butoxy-(2(methacryloyloxy)ethyl)-dimethyl-2-oxoethanaminium (CB-tBu), which was carried out in
anhydrous dimethylformamide (DMF), initiated by N-hydroxysuccinimide 2-bromopropanoate
and catalyzed by Cu(I)Br/1,1,4,7,10,10-hexamethyltriethylenetetramine (HMTETA). The
resulting NHS-PCB-tBu was purified through precipitation in acetone, and later treated with
trifluoroacetic acid to obtain PCB-NHS, which was further precipitated in ethyl ether, and dried
under vacuum condition.
4.2.3 Synthesis of PCB-insulin and PEG-insulin
Conjugates of PCB-insulin and PEG-insulin were synthesized by reacting NHS ester
groups of the polymer with available amine groups on the protein. Typically, insulin (1 mg/mL)
was dissolved in 0.1 M Na2CO3 buffer. The insulin stock solution was homogeneously divided
into three portions, with one as free insulin sample, and the other two for conjugation with PCB
and PEG, respectively. For the conjugation reaction, pre-dissolved PCB-NHS 5K or PEG-NHS
5K was added into the insulin solution at polymer: insulin molar ratio = 1.2:1, and the reaction
mixture was stirred at 700 round/min rate at 0 °C, for one hour to obtain the PCB-insulin or
PEG-insulin rough products. After the reaction, the buffer was adjusted to pH 7.4 by HCl. To
obtain PEG-insulin and PCB-insulin where most of the three amines of insulin were conjugated
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with PEG or PCB, pre-dissolved PCB-NHS 5K or PEG-NHS 5K was added into the insulin
solution at polymer: insulin molar ratio = 20:1 in 0.2 M HEPES buffer, and the reaction mixture
was stirred at 400 round/min rate for 40 hours.

4.2.4 Purification of PCB-insulin and PEG-insulin
To purify PCB-insulin and PEG-insulin, the rough conjugation products were placed in a
dialysis kit (6-8 kDa MWCO, Sigma-Aldrich). The MW cut off retains the polymer-insulin
conjugates, but allows both free insulin and unconjugated PCB-NHS or PEG-NHS to go through
the membrane. Completion of purification was indicated by observing no unconjugated insulin
or polymer partitioned to the solvent phase outside of the dialysis tubing. Unconjugated insulin
can be detected using UV-vis spectrometer (at 276 nm). Also, both unconjugated insulin and
polymer can be sensitively detected by DLS (Zetasizer Nano-ZS, Malvern); a dialysate solution
with the count rate (the number of photons detected per second) as low as that of pure water
indicating that the solution is free of insulin or polymer. The purified polymer-insulin samples
were desalted using a PD-10 column and freeze-dried for storage. To quantify the molar
concentration of purified PCB-insulin and PEG-insulin solution sample, both methods of UV-vis
absorbance (276 nm) and a Mercodia human insulin ELISA assay were used.
4.2.5 Other Characterization
The hydrodynamic sizes of the insulin and its conjugate samples were measured by a DLS
method using a Malvern Nano-ZS Zetasizer at 25 oC. The samples of free insulin, PEG-insulin
and PCB-insulin were dissolved in 0.2M HEPES buffer and analyzed on an Autoflex III matrixassisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF-MS, Bruker
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Daltonics). The mass spectra were collected with a repetition rate of 100 Hz, accelerating voltage
of 19 kV and an average of 700 shots. The data were analyzed with Biotools program (Bruker).
CD spectra were collected by using a Chirascan spectrophotometer from Applied
Photophysics at 25 oC. Insulin samples were dissolved in PBS buffer at 0.2 mg/mL. The CD
spectra were measured from 200 to 250 nm with the light-path length of 1 mm. The scanning
speed of CD spectra measurement was set at 200 nm/min. Each spectrum was the average of
three scans to increase the signal-to-noise ratio of the measurements. The secondary structure
proportions for insulin and its conjugates were analyzed using CDSSTR software.
For insulin bioactivity test, about 25,000 CHO-M1 cells/well (ATCC) were seeded in a 96well tissue culture treated plate and incubate for 24 h before being cultured in serum-free
medium. These cells were then treated with 10 μg/mL native insulin, PEG-insulin, and PCBinsulin samples, respectively, for 45 minutes. Then cells were lysed, and a commercially
available kit (Cisbio) was used to assay phosphorylated AKT at Ser473. The fluorescence
emission at 665 and 620 nm was measured on an HTRF reader (BioTek, USA).

4.2.6 Animal Experiments
All animal experiments were performed according to the National Institute of Health (NIH)
guidelines for animal research under a protocol approved by the Institutional Animal Care and
Use Committee (IACUC) at Wayne State University. To establish streptozotocin (STZ)-induced
diabetic mice model, healthy mice (C57BL/6J, male, 6-8 weeks of age, Jackson Lab) received a
daily i.p. injection of 5 mg/mL STZ at 50 mg/kg for 5 consecutive days. 17 days after the first
injection, body weight and blood glucose were measured to confirm the diabetic status. Only
mice whose nonfasted blood glucose levels are above 300 mg/dL for two consecutive days were
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considered diabetic for further in vivo testing. To examine the blood glucose lowering effect of
insulin after conjugation, diabetic mice received 10 nmol/kg body weight of free insulin, crude
products and purified forms of PCB-insulin and PEG-insulin through tail vein injection (mouse
group size = 6). 5-10 µL blood samples were collected from the tail for glucose testing using a
clarity plus blood-glucose meter at predetermined time intervals. The mice fasted during the
glucose testing period. To examine blood circulation profile of insulin after conjugation, diabetic
mice received 10 nmol/kg body weight of free insulin, purified PCB-insulin and purified PEGinsulin through the tail vein (mouse group size = 6). At predetermined time intervals, 25 µL
blood samples were collected from the tail vein. The insulin concentration in the blood serum
was determined using a Mercodia human insulin ELISA assay. The mice fasted during the blood
insulin testing period.

4.3 Results and Discussion
Zwitterionic polymer materials have attracted increasing attention as novel nonfouling materials.[63] Particles with surfaces modified with zwitterionic polymers, such as
PCB, have been found to efficiently avoid interactions with plasma proteins and uptake
by the reticuloendothelial system (RES),[63a,

64]

show significantly prolonged blood

circulation half-life (improved PK),[32, 64] and demonstrated reduced immunogenicity.[65]
Here, the general strategy in obtaining PCB-insulin conjugate is by reacting an Nhydroxysuccinimide (NHS) ester terminated PCB with the available amine groups of
human recombinant insulin (Figure 4-1a). To prepare PCB-insulin conjugate, NHS ester
terminated PCB (PCB-NHS) was synthesized following established procedures.[32] The
MW for PCB-NHS is ~5000 Da as previously reported: Mn = 4890 Da determined by 1H
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NMR, Mn= 5410 Da, polydispersity = 1.03 characterized by gel permeation
chromatography (GPC).[32] Then PCB-NHS was reacted with the amine group of insulin
at PCB-NHS: insulin molar ratio of 1.2:1 to synthesize PCB-insulin conjugate. The
reaction was conducted in a Na2CO3 solution (pH > 10) at which condition the acylation
may occur at any of the three amines (GlyA1, PheB1, or LysB29), but is prioritized at
epsilon amine of LysB29.[66] The LysB29 epsilon amine is the most basic with a pKa of
approximately 10. Hence at pH = 10, LysB29 is preferred for most nucleophilic agents.
In a similar way, PEG-insulin control was obtained by reacting a commercially available
PEG-NHS (5000 Da, MW) with insulin. A purification method was developed using a 6-8
kDa MWCO dialysis kit to remove unreacted insulin (~5800 Da) and unconjugated PCBNHS or PEG-NHS (about 5000 Da). The purified PCB-insulin and PEG-insulin were
analyzed by MALDI-TOF MS. (Figure 4-1b). The obtained PCB-insulin and PEGinsulin were NOT further separated to obtain their respective purified isoforms (i.e., a
polymer conjugated to LysB29 of insulin) before evaluating their PK and bioactivity.
The obtained PCB-insulin was first evaluated for its improved blood circulating
potential or PK. The hydrodynamic size of conjugated proteins is a major factor
determining theirs in vivo blood circulation behavior.[14n,

62a, 67]

An increase in

hydrodynamic size typically supersedes the renal ultrafiltration cut-off and reduces the
glomerular filtration of modified proteins. A prolonged blood circulation half-life has
been extensively reported for PEGylated proteins.[68] We measured the hydrodynamic size
of conjugated insulin with dynamic light scattering (DLS) method by using a Malvern
Nano-ZS Zetasizer (Figure 4-2a). The hydrodynamic sizes of insulin, PEG-insulin, and
PCB-insulin in pH 8.4 HEPES buffer are 1.4±0.2 nm, 2.8±0.7 nm, and 2.2±0.6 nm,
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respectively (average ± standard deviation, n=3). Similar to PEG-insulin, there is a
significant hydrodynamic size increase for PCB-insulin over native insulin, implying
potentially protracted blood circulating lifetime for PCB-insulin.
The PK of PCB-insulin was examined in a diabetic mouse model. All animal
experiments were performed according to the National Institutes of Health (NIH)
guidelines for animal research under a protocol approved by the Institutional Animal Care
and Use Committee (IACUC) at Wayne State University. C57BL/6 mice received a daily
i.p. injection of 5 mg/mL streptozocin (STZ) at 50 mg/kg for 5 consecutive days. STZmice were placed on a nonfasted regular diet. 17 days after the first injection, weight and
blood glucose were measured to confirm diabetic status. Only mice whose nonfasted
blood glucose levels are above 300 mg/dL for two consecutive days were considered
diabetic. Insulin and purified polymer-insulin conjugates were injected into three groups
of diabetic mice through the tail vein at an equal molar dose of 10 nmol/kg. Blood
samples were collected at various time intervals, and the concentration of serum insulin
was quantified with human insulin ELISA assay (Figure 4-2b). The relative area under
the curve (AUC) was calculated, and the blood circulation half-life (t1/2) was obtained to
fit a one-compartment model[32] (Table 4-1). The AUCs for both PCB-insulin and PEGinsulin are larger than that of native insulin. The relative AUC for PCB-insulin is almost
1.43 times of that of native insulin. t1/2 for PCB-insulin (4.2 h) and PEG-insulin (3.6 h) are
significantly longer than free insulin (2 h). Typically, elimination half-life indicates the
time necessary for the amount or the concentration of drug in serum or plasma, to reduce
by 50%. Half-life is usually regarded as the most reliable indicator of the rate of drug
removal by the body[69]. The rate of removal is expected to be slow when the half-life is
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long, which implies a long effective duration of the drug in the blood circulation[70]. The
data here indicate that the modified insulin using both PCB and PEG showed prolonged
blood circulation effect compared with naked insulin.
The obtained PCB-insulin was secondly evaluated for potential bioactivity change. the
effect of polymer conjugation on the secondary structure of insulin was studied, since proteins
generally require stabilized structures to contain their particular bioactivity.[71] Circular
Dichroism (CD) Spectroscopy has been widely involved in characterizing the secondary
conformation of insulin and its derivatives,[68a, 72] and was used here to evaluate free insulin,
PCB-insulin, and PEG-insulin (spectra in Figure 4-3a; quantified results of secondary structures
in Table 2). We found that the percentage of α-helix structure for PEG-insulin is 46%, and is
slightly less than that for free insulin which is 50%. The random coil structure proportion for
PEG-insulin is 30% and is more than 24% for free insulin. A similar trend has been reported in
the literature for PEG conjugated insulin,[68a] indicating a slightly destabilizing effect on the
protein structure. For the CD spectrum of PCB-insulin (Figure 4-3a), there is an obvious
decrease of the negative peak at 222 nm, indicating the increase of α-helix structure. Quantified
results (Table 2) show that the α-helix structure proportion of PCB-insulin is 53% (slightly more
than 50% of insulin), and the random coil structure proportion is 23% (a little less than 24% of
insulin). This suggests that the conjugation of PCB has a moderate stabilizing effect on the
secondary structure of insulin, and implies the potential retention of insulin bioactivity after PCB
conjugation.
In vitro activity of PCB-insulin was tested using a cell-based protein kinase B
phosphorylation assay. Briefly, 25,000 CHO-M1 cells/well (ATCC) were seeded in a 96well tissue culture treated plate and incubated for 24 h before being cultured in serum-free
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medium overnight (12 hours). These cells were then treated with 50 µL of native insulin,
rough products of PEG-insulin and PCB-insulin without any purification (containing both
conjugated and unconjugated insulin), or purified products of PEG-insulin and PCBinsulin (containing solely of conjugated insulin) for 45 minutes. The effective insulin
concentration in each of the sample was maintained at 2 nmol/mL. For rough conjugate
products (unpurified), the effective insulin concentration can be easily controlled by the
feeding molar content of insulin for the conjugation reaction. For purified conjugate
products, we used both UV-vis absorbance (276 nm), and a Mercodia human insulin
ELISA assay to quantify effective insulin concentration. Then treated cells were lysed,
and a commercially available kit (Cisbio) was used to assay phosphorylated AKT at
Ser473. Figure 4-3B indicates that there was no significant decrease of in vitro
bioactivity of both the rough and purified zwitterionic PCB-insulin, but decrease on the
PEG-insulin was observed. The purified PEG-insulin lost ~27% activity compared with
native insulin.
The obtained PCB-insulin was lastly evaluated for its in vivo pharmacological
activity. STZ induced diabetic was treated with i.v. injection of PCB-insulin and their
blood glucose concentration at various time points following the injection were
monitored. Diabetic mice received free insulin, as well as PCB-insulin and PEG-insulin
rough products without any purification (containing both conjugated and unconjugated
insulin), to the mice, at the dose of 10 nmol insulin or its conjugate /Kg (for native insulin
dose, 10 nmol/kg = 1.5 IU/kg). The in vivo pharmacological activity of insulin samples
was evaluated by quantifying the area above the curve (AAC) of the relative intensity of
blood glucose concentration. In Figure 4-3C, there was no significant difference of blood
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glucose lowering abilities between PEG-insulin and native insulin (student t-test).
However, PCB-insulin shows significantly higher blood glucose lowering ability than
native insulin at p < 0.05 in a student t-test (Figure 4-3C). We further injected free
insulin, as well as purified PCB-insulin and PEG-insulin samples to the mice at the dose
of 10 nmol/Kg. The purified PEG-insulin did not show any better glucose lowering effect
than native insulin (Figure 4-3D). But the purified PCB-insulin sample had even higher
blood glucose lowering ability than native insulin (Figure 4-3D), and then its nonpurified form as well (by comparing Figure 4-3C and 4-3D). The pharmacological
activity of PEG-insulin is about 97.5% which showed no significant difference comparing
with that of native insulin (100%). For PCB-insulin, pharmacological activity is about
124.3% which showed significance at p < 0.005 by comparing the AACs for PCB-insulin
and free insulin in a student t-test.
It should be noted that a typical rough product of PCB-insulin contains
unconjugated insulin, PCB-conjugated insulin and unconjugated PCB polymer. If PCB
polymers were proved to be non-toxic (in a future work), such rough product can
potentially be directly used as a medicine to minimize the cost by not wasting the unconjugated insulin in a purification process.
Despite many possible factors proposed, long half-life in blood circulation has been
considered to be the most important reason responsive to the high pharmacological
activity of proteins.[26a, 73] The increased in vivo pharmacological activity of PCB-insulin
was attributed to its prolonged blood circulation lifetime plus the retained in vitro
bioactivity. PEG-insulin also showed a longer blood circulation character, but because of
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the loss of in vitro bioactivity, its overall in vivo pharmacological activity did not show
improvement over native insulin.
The reason for PCB conjugation to retain in vitro bioactivity of the modified insulin
might share a similar mechanism to a previously reported PCB conjugated enzyme
system. PCB conjugation to α-chymotrypsin did not sacrifice the protein’s catalytic
activity, which has been attributed to the superhydrophilic nature of PCB polymer that did
not interfere with the hydrophobic-hydrophobic, substrate-binding site interaction.[26a] By
contrast, PEG weakened such interaction with its amphiphilic nature and imposed steric
hindrance.[26a] Retained bioactivity of PCB-insulin can be similarly explained by the
unimpeded insulin ligand-receptor interaction.
It should be noted that our coupling condition was controlled to have one PCB
polymer chain to be conjugated preferentially at LysB29 of insulin to produce PCBinsulin of even higher in vivo pharmacological activity than native insulin. Nevertheless,
when PCB was conjugated to three amines of insulin (Figure 4-4), there was a drastic
loss of in vitro bioactivity (Figure 4-5A) and the in vivo pharmacological activity as well
(Figure 4-5B), potentially due to the occupation of Gly A1 near to the insulin’s active
site.
To summarize, results in this project indicate that one-PCB-chain modification per
insulin obtained from conjugation chemistry shows improved PK, retained in vitro
bioactivity and increased in vivo pharmacological activity of lowering blood glucose
compared with native insulin.
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Figure 4-1. (a) The schematic illustration of PCB conjugation with native recombinant human insulin.
There are three amino acids with free amino groups (GlyA1, PheB1, and Lys B29) that are available for
PCB conjugation. The disulfide bonds in insulin were labeled with yellow sticks. (b) MALDI-TOF Mass
spectra of native insulin, PEG-insulin, and PCB-insulin.
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Fig. 4-2 (a) Hydrodynamic sizes for insulin, PEG-insulin, and PCB-insulin, respectively, as measured by
DLS. Samples were dissolved in 0.2 M pH8.4 HEPES buffer. (b) The serum insulin concentration as a
function of time after the tail vein injection of free insulin, PEG-insulin, and PCB-insulin, respectively.
The data are presented as the percentage of the initial values of serum insulin concentration over time ±
standard deviation (n=6).

Samples

Relative area under

Half-life

the curve (AUC)

elimination
time (t1/2) (h)

Insulin

341 ±24

2.0 ±0.3

PEG-insulin

447 ±30

3.6 ±0.3

PCB-insulin

466 ±34

4.2 ±0.3

Table 4-1: The relative area under the curve (AUC) and elimination half-life (t1/2) of native insulin
and its conjugates in blood serum. Data are illustrated by average ±standard deviation, n=6.
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A

C

D

Fig. 4-3. (A) Circular dichroism (CD) spectra of native insulin, PEG-insulin, and PCB-insulin (0.2
mg/mL insulin or conjugates at 0.2 M pH8.2 PBS buffer). (B) The bioactivity of native insulin, rough
PEG-insulin, purified PEG-insulin, rough PCB-insulin, and purified PCB-insulin, as measured by
phosphorylation of the insulin receptor in vitro. The relative activity was presented as the percentage
relative to native insulin ± standard deviation (n=6). *p < 0.05, **p < 0.01, n.s. = not significant. The
relative blood glucose concentration as a function of time after the tail vein injection of free insulin, PEGinsulin, or PCB-insulin (C) before and (D) after purifying insulin conjugate products. The data are
presented as the percentage of the initial values of blood glucose concentration ± standard deviation
(n=6).
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-

Sample

helix

-structure
(-turn and -

Random coil

sheet)
Free insulin

50%

26%

24%

PEG-insulin

46%

24%

30%

PCB-insulin

53%

24%

23%

Table 4-2: The secondary structure proportion of insulin samples measured from Circular
Dichroism (CD) Spectroscopy

Figure 4-4: MALDI-TOF Mass spectra of native insulin, purified PEG-insulin and purified PCB-insulin
where most of the three amines of insulin were conjugated with PEG or PCB.
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Figure 4-5: (A) The bioactivity of native insulin, rough PEG-insulin, purified PEG-insulin, rough PCBinsulin and purified PCB-insulin, respectively, as measured by phosphorylation of the insulin receptor in
vitro. For the polymer-insulin tested, most of the three amines of insulin were conjugated with PEG or
PCB. The relative activity was presented as the percentage of native insulin (n=6). *** p < 0.001. (B)
The relative blood glucose concentration as a function of time after the tail vein injection of free insulin,
rough PEG-insulin, and rough PCB-insulin (before purifying insulin conjugate products). The data are
presented as the percentage of the initial values of blood glucose concentration ± standard deviation (n=6).
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CHAPTER 5. CONCLUSION
The focus of this thesis is the potential of the zwitterionic PCBs for drug delivery
applications, including constructing micelles for chemo drug delivery and modifying glucose
regulating proteins. Specifically, this thesis involves the discovery of the ultra-low CMC
property of DSPE-PCB 5K micelle and the enhanced therapeutic performance of
docetaxel/DSPE-PCB 5K formulation. In addition, zwitterionic PCB was used to conjugate with
insulin and was found to be able to mitigate the long-lasting bioactivity loss problem when
proteins were modified with current polymers.
Compared with common conventional micelles, DSPE-PCB 5K showed ultra-low CMC
property and high colloid stability in clinically relevant conditions. Such stabilizing effect
appeared to be powerful; It was found that even when a zwitterionic moiety or polymer was
added into a micelle solution (not chemically modifying the micelle), the existing micelle
molecules in the new solution was stabilized at a concentration below its inherent CMC. It is
further demonstrated that the ultra-low CMC micelle could stabilize hydrophobic cargo (without
micelle dissociation) in diluted conditions and the findings reported here are expected to help the
design of other micelle-based formulations to improve their stability. Using a melanoma tumor
model, docetaxel/DSPE-PCB 5K formulation showed excellent anti-tumor performance by
eliminating tumors in mice without a sign of recurrence. It is expected that the novel micelle
system demonstrated here can encapsulate other commercially available chemo drugs and further
promoted their therapeutic performance compared with their current micellar formulations.
Polymer-protein conjugation suffered from the bioactivity loss of protein since it was
developed. It was found that PCB-insulin conjugation via simple one-step coupling chemistry
does not compromise the bioactivity of insulin as confirmed in the in vitro test. In vivo study
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indicated enhanced blood circulation time of the PCB-insulin conjugate. Combined with the
advantage of improved pharmacokinetics and the prevention of bioactivity loss, PCB-insulin
showed better glucose regulation effects in vivo compared with PEGylated insulin and
unmodified natural insulin. This finding is likely to inspired future highly effective polymerprotein conjugates to be developed.
In the future, it is of interest to further explore the application of zwitterionic polymer in
the drug delivery field based on these two projects. For the ultralow CMC micelle work, it will
be of interest to test the encapsulation of other hydrophobic drugs and study anti-tumor
performance in other types of cancer models. Further, the scale-up issue of producing ultralow
zwitterionic micelles requires investigation for potential future commercialization and clinical
trials. For the polymer-protein conjugation work, we are eager to know the mitigation of
bioactivity loss of the modified protein can work on other types of therapeutic proteins. This will
invovle similar studies to this dissertation by conjugating PCB to a few protein drugs of high
therapeutic value and measuring the bioactivity of the protein after conjugation.
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This dissertation focuses on the applications of zwitterionic polymer materials in drug
delivery. In one project, zwitterionic polymers were used to construct micelle surfactants. The
zwitterionic micelles were found to have an ultralow (< 2.7 × 10-6 mM) critical micelle
concentration (CMC) and a potential mechanism for zwitterionic micelles achieving the ultralow
CMC property has been studied. Based on the ultralow CMC feature, zwitterionic micelles were
used to prepare a formulation of commercial antitumor drug docetaxel, and the resulting
formulation showed excellent antitumor performance. In another project, zwitterionic polymers
were used to modify the protein drug insulin via conjugation reaction. Compared with current
protein modification methods, such as PEGylation, zwitterionic polymer conjugation increased
24% pharmacological activity compared with native insulin without compromising bioactivity.
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